DPP4 Inhibitors and COVID-19–Holy Grail or Another Dead End?

A novel coronavirus disease, COVID-19, has emerged as a global public health issue. Clinical course of disease significantly correlates with the occurrence of some comorbidities, among them type 2 diabetes. According to recent structural studies the dipeptidyl peptidase 4, a key molecule in the path...

Descripción completa

Detalles Bibliográficos
Autores principales: Krejner-Bienias, Alicja, Grzela, Katarzyna, Grzela, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850901/
https://www.ncbi.nlm.nih.gov/pubmed/33527308
http://dx.doi.org/10.1007/s00005-020-00602-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850901/
https://www.ncbi.nlm.nih.gov/pubmed/33527308
http://dx.doi.org/10.1007/s00005-020-00602-5

Ejemplares similares